{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T15:03:36Z","timestamp":1793286216016,"version":"4.5.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,14]]},"DOI":"10.7759\/cureus.84121","type":"journal-article","created":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T19:40:25Z","timestamp":1747251625000},"source":"Crossref","is-referenced-by-count":3,"title":["Rapid-Onset Myositis and Myocarditis Following Dual Immune Checkpoint Inhibitor Therapy With Nivolumab and Ipilimumab for Gastric Adenocarcinoma: A Case Report"],"prefix":"10.7759","author":[{"given":"Steven B","family":"Barker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeoluwa","family":"Adewuyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathol-042020-042741","article-title":"Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance","volume":"16","author":"Bagchi S","year":"2021","unstructured":"Bagchi S, Yuan R, Engleman EG. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu Rev Pathol. 2021, 16:223-49. 10.1146\/annurev-pathol-042020-042741","journal-title":"Annu Rev Pathol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck M","year":"2016","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, et al.. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016, 375:1823-33. 10.1056\/NEJMoa1606774","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert C","year":"2015","unstructured":"Robert C, Long GV, Brady B, et al.. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015, 372:320-30. 10.1056\/NEJMoa1412082","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-0160-6","article-title":"Immune-related adverse events of checkpoint inhibitors","volume":"6","author":"Ramos-Casals M","year":"2020","unstructured":"Ramos-Casals M, Brahmer JR, Callahan MK, et al.. Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers. 2020, 6:38. 10.1038\/s41572-020-0160-6","journal-title":"Nat Rev Dis Primers"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21093054","article-title":"Immune checkpoint inhibitor-related myositis: from biology to bedside","volume":"21","author":"Solimando AG","year":"2020","unstructured":"Solimando AG, Crudele L, Leone P, et al.. Immune checkpoint inhibitor-related myositis: from biology to bedside. Int J Mol Sci. 2020, 21:10.3390\/ijms21093054","journal-title":"Int J Mol Sci"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins F","year":"2019","unstructured":"Martins F, Sofiya L, Sykiotis GP, et al.. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol. 2019, 16:563-80. 10.1038\/s41571-019-0218-0","journal-title":"Nat Rev Clin Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.14740\/jocmr3750","article-title":"Adverse effects of immune checkpoint inhibitors (programmed death-1 inhibitors and cytotoxic T-lymphocyte-associated protein-4 inhibitors): results of a retrospective study","volume":"11","author":"Bajwa R","year":"2019","unstructured":"Bajwa R, Cheema A, Khan T, et al.. Adverse effects of immune checkpoint inhibitors (programmed death-1 inhibitors and cytotoxic T-lymphocyte-associated protein-4 inhibitors): results of a retrospective study. J Clin Med Res. 2019, 11:225-36. 10.14740\/jocmr3750","journal-title":"J Clin Med Res"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.09.033","article-title":"Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors","volume":"106","author":"Moreira A","year":"2019","unstructured":"Moreira A, Loquai C, Pf\u00f6hler C, et al.. Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors. Eur J Cancer. 2019, 106:12-23. 10.1016\/j.ejca.2018.09.033","journal-title":"Eur J Cancer"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson DB","year":"2016","unstructured":"Johnson DB, Balko JM, Compton ML, et al.. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016, 375:1749-55. 10.1056\/NEJMoa1609214","journal-title":"N Engl J Med"},{"key":"ref10","unstructured":"National Comprehensive Cancer Network - Clinical Practice Guidelines in Oncology. gastric cancer. (2024). Accessed: October 16, 2024: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/gastric.pdf."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0774-y","article-title":"Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature","volume":"7","author":"Safa H","year":"2019","unstructured":"Safa H, Johnson DH, Trinh VA, et al.. Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature. J Immunother Cancer. 2019, 7:319. 10.1186\/s40425-019-0774-y","journal-title":"J Immunother Cancer"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.803410","article-title":"Incidence and distinct features of immune checkpoint inhibitor-related myositis from idiopathic inflammatory myositis: a single-center experience with systematic literature review and meta-analysis","volume":"12","author":"Hamada N","year":"2021","unstructured":"Hamada N, Maeda A, Takase-Minegishi K, et al.. Incidence and distinct features of immune checkpoint inhibitor-related myositis from idiopathic inflammatory myositis: a single-center experience with systematic literature review and meta-analysis. Front Immunol. 2021, 12:803410. 10.3389\/fimmu.2021.803410","journal-title":"Front Immunol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2020-235199","article-title":"Immune-related myositis resulting from combination therapy of ipilimumab and nivolumab in patient with metastatic renal cell carcinoma","volume":"13","author":"Okubo N","year":"2020","unstructured":"Okubo N, Kijima T, Nukui A, Kamai T. Immune-related myositis resulting from combination therapy of ipilimumab and nivolumab in patient with metastatic renal cell carcinoma. BMJ Case Rep. 2020, 13:e235199. 10.1136\/bcr-2020-235199","journal-title":"BMJ Case Rep"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.5152\/eurjrheum.2019.18159","article-title":"Autoimmune myositis and myasthenia gravis resulting from a combination therapy with nivolumab and ipilimumab for metastatic melanoma","volume":"6","author":"Sutaria R","year":"2019","unstructured":"Sutaria R, Patel P, Danve A. Autoimmune myositis and myasthenia gravis resulting from a combination therapy with nivolumab and ipilimumab for metastatic melanoma. Eur J Rheumatol. 2019, 6:153-4. 10.5152\/eurjrheum.2019.18159","journal-title":"Eur J Rheumatol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0000000000000251","article-title":"Myocarditis as an immune-related adverse event with ipilimumab\/nivolumab combination therapy for metastatic melanoma","volume":"26","author":"Mehta A","year":"2016","unstructured":"Mehta A, Gupta A, Hannallah F, Koshy T, Reimold S. Myocarditis as an immune-related adverse event with ipilimumab\/nivolumab combination therapy for metastatic melanoma. Melanoma Res. 2016, 26:319-20. 10.1097\/CMR.0000000000000251","journal-title":"Melanoma Res"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1080\/01676830.2017.1423349","article-title":"Complete ophthalmoplegia in Ipilmumab and Nivolumab combination treatment for metastatic melanoma","volume":"37","author":"Alnabulsi R","year":"2018","unstructured":"Alnabulsi R, Hussain A, DeAngelis D. Complete ophthalmoplegia in Ipilmumab and Nivolumab combination treatment for metastatic melanoma. Orbit. 2018, 37:381-4. 10.1080\/01676830.2017.1423349","journal-title":"Orbit"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcr\/ytab342","article-title":"A case report of immune checkpoint inhibitor-related steroid-refractory myocarditis and myasthenia gravis-like myositis treated with abatacept and mycophenolate mofetil","volume":"5","author":"Jespersen MS","year":"2021","unstructured":"Jespersen MS, Fan\u00f8 S, Sten\u00f8r C, M\u00f8ller AK. A case report of immune checkpoint inhibitor-related steroid-refractory myocarditis and myasthenia gravis-like myositis treated with abatacept and mycophenolate mofetil. Eur Heart J Case Rep. 2021, 5:ytab342. 10.1093\/ehjcr\/ytab342","journal-title":"Eur Heart J Case Rep"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider BJ","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD, et al.. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021, 39:4073-126. 10.1200\/JCO.21.01440","journal-title":"J Clin Oncol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1097\/FJC.0000000000001456","article-title":"Treatment of immune checkpoint inhibitor-associated myocarditis","volume":"83","author":"Heemelaar JC","year":"2024","unstructured":"Heemelaar JC, Louisa M, Neilan TG. Treatment of immune checkpoint inhibitor-associated myocarditis. J Cardiovasc Pharmacol. 2024, 83:384-91. 10.1097\/FJC.0000000000001456","journal-title":"J Cardiovasc Pharmacol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/358171-rapid-onset-myositis-and-myocarditis-following-dual-immune-checkpoint-inhibitor-therapy-with-nivolumab-and-ipilimumab-for-gastric-adenocarcinoma-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T19:40:26Z","timestamp":1747251626000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/358171-rapid-onset-myositis-and-myocarditis-following-dual-immune-checkpoint-inhibitor-therapy-with-nivolumab-and-ipilimumab-for-gastric-adenocarcinoma-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,14]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.84121","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5,14]]}}}